Clinical trials: PCNSL, open to volunteers
Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
The aim of the trial is to evaluate the molecular characteristics and MDD/MRD of B-NHL in pediatric patients in order to identify on the one hand the very high risk group and to prescribe them more intensive treatment on the…
- Conditions
- Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma, Primary Mediastinal Lymphoma, Primary CNS Lymphoma
- Trial name
- NCT05518383
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
PCNSL
A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
This is a prospective, multicenter, single-arm, open Phase Ib/II clinical study to explore the safety and efficacy of pomadomide in combination with rituximab and methotrexate (RPM) in newly diagnosed primary central nervous…
- Trial name
- NCT06554561
- Testing
- Pomalidomide, Rituximab, Methotrexate
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lymphoma, B-Cell
Phase Ib Clinical Study of Keynatinib
The purpose of this study is to evaluate the efficacy, safety, PK characteristics in subjects with relapsed/refractory B-cell lymphoma.
- Trial name
- NCT04807881
- Testing
- Keynatinib
- Where
- 4 sites in China
- Volunteers
- 75 people
- Sponsor
- Medolution Ltd.
Lymphoma
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma…
- Trial name
- NCT07015242
- Testing
- Rituximab, Methotrexate, Procarbazine
- Where
- 40 sites in United States, France and 1 more
- Volunteers
- 65 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side…
- Trial name
- NCT07137494
- Testing
- MB-CART19.1 Cellular Therapy
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
- Trial name
- NCT05131022
- Testing
- NX-5948
- Where
- 62 sites in United States, France and 6 more
- Volunteers
- 572 people
- Sponsor
- Nurix Therapeutics, Inc.
Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system…
- Conditions
- Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
- Trial name
- NCT07082868
- Testing
- ibrutinib, Epcoritamab
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
- Trial name
- NCT04906096
- Testing
- PAXALISIB
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Lakshmi Nayak, MD
Primary CNS Lymphoma (PCNSL)
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
The purpose of this phase 2 study is to evaluate the efficacy and safety of epcoritamab in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and…
- Trial name
- E-REVRI (NCT06931652)
- Testing
- Epcoritamab
- Where
- 13 sites in France
- Volunteers
- 60 people
- Sponsor
- The Lymphoma Academic Research Organisation
Vitreoretinal Lymphoma
Multicentre Implementation and Validation of a Molecular Diagnostic for VitreoRetinal Lymphoma
The goal of this observational study is to gain new insights into the changes in proteins, genes and other molecular biological substances in the aqueous humour, vitreous humour, blood serum and, in rare cases, retina/choroid…
- Trial name
- DecodeVRL (NCT05841914)
- Where
- Germany
- Volunteers
- 220 people
- Sponsor
- Vinodh Kakkassery, MD
Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL)
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T…
- Conditions
- Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma
- Trial name
- NCT04186520
- Testing
- 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Medical College of Wisconsin
Non-Hodgkin Lymphoma
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)
- Trial name
- MTR² (NCT05583071)
- Testing
- Tafasitamab, Lenalidomide, Rituximab
- Where
- 6 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University of Cologne
Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL)
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
This open-label, single arm phase 1 trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with…
- Conditions
- Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL), Mantle Cell Lymphoma (MCL), CNS Lymphoma
- Trial name
- NCT05098613
- Testing
- CD19x22 CAR T Cells
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Colorado, Denver
Diffuse Large B Cell Lymphoma
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients.
- Trial name
- CNS-PHLAT (NCT06687772)
- Testing
- Thiotepa, Carmustine, Autologous Stem Cell Transplant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Primary Central Nervous System Lymphoma (PCNSL)
Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma
To evaluate the efficacy and safety of relmacabtagene autoleucel combined with autologous hematopoietic stem cell transplantation, orelabrutinib, and sintilimab as first-line or relapsed/refractory treatment for primary central…
- Trial name
- NCT07198464
- Testing
- Relmacabtagene autoleucel and transplantation
- Volunteers
- 30 people
- Sponsor
- Zhengzhou University
Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib
Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL
This is a prospective, single-arm, phase II clinical study evaluating the efficacy and safety of Zanubrutinib (a BTK inhibitor) plus Lenalidomide (an immunomodulatory drug) in frail elderly patients with newly diagnosed primary…
- Conditions
- Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib, Lenalidomide, Frail Elderly
- Trial name
- NCT07839247
- Testing
- Zanubrutinib, Lenalidomide
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Xiaohui Ren
Primary CNS Lymphoma (PCNSL)
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
An Open, Single treatment arm, Multi-center, Prospective, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) combined with Rituximab and Lenalidomide as a Salvage Therapy for Patients with Relapsed or Refractory…
- Trial name
- POTENTIAL-P (NCT06737250)
- Testing
- R2P -> RP
- Where
- 10 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- NOBO Medicine
Primary Central Nervous System Lymphoma
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.
- Trial name
- NCT02657785
- Testing
- R-IDARAM plus intrathecal chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Navy General Hospital, Beijing
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or…
- Conditions
- Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
- Trial name
- NCT03328078
- Testing
- Emavusertib, Ibrutinib
- Where
- 45 sites in United States, Czechia and 5 more
- Volunteers
- 152 people
- Sponsor
- Curis, Inc.
Primary Central Nervous System Lymphoma
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
Most patients being diagnosed with primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) are 60 years or older.
- Trial name
- PRIMA-CNS (NCT06830421)
- Testing
- R-MP and Procarbazine maintenance, R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT
- Where
- 35 sites in Germany
- Volunteers
- 340 people
- Sponsor
- University Hospital Freiburg